Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Randomised, Phase IV Study, to Assess the Efficacy and Safety of Tildrakizumab in Patients With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy (TRANSITION)

NCT04263610 is registered in ClinicalTrials.gov with Almirall, S.A. as lead sponsor.

NCT NCT04263610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04263610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Randomised, Phase IV Study, to Assess the Efficacy and Safety of Tildrakizumab in Patients With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy (TRANSITION)
Lead sponsor
Almirall, S.A.
Phase
Phase 4
Overall status
Completed
Start date
September 4, 2019
Completion date
February 16, 2022
Enrollment
190 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis